Trial Profile

Proxy triplet trial of ACH-3102 and sovaprevir with sofosbuvir in patients with hepatitis C

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odalasvir (Primary) ; Sofosbuvir; Sovaprevir
Indications Hepatitis C
Focus Therapeutic Use

Most Recent Events

17 Sep 2015 According to a company media release, Achillion Pharmaceuticals expects to initiate this trial by early 2017.
16 Mar 2015 New trial record
05 Mar 2015 SVR4 results are expected in the second half of 2015, according to an Achillion Pharmaceuticals media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com